Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On watch for reversal
NewLink Genetics Announces Review of Clinical Programs
Source: GlobeNewswire Inc.
NewLink Genetics Corporation (NASDAQ:NLNK) today announced a review of its clinical programs.
This morning’s announcement by Incyte and Merck on the ECHO-301 trial for patients with advanced melanoma is a disappointing result for the IDO field. Indoximod, NewLink Genetics’ IDO pathway inhibitor, has a differentiated mechanism of action (MOA) which may demonstrate clinical benefit for patients where direct enzymatic inhibitors have not. In light of Incyte’s announcement, however, NewLink is undertaking a review of its clinical programs and will provide an update when it is completed.
NewLink Genetics has generated data for indoximod across several indications, and in combination with different modalities, suggesting the potential for indoximod to improve the outcomes for patients with cancer. The Company will present additional data at AACR next week, including a poster presentation further supporting indoximod’s differentiated MOA and a plenary session presenting encouraging early clinical data of indoximod plus radiation for pediatric patients with diffuse intrinsic pontine glioma (DIPG), a rare and lethal form of brain cancer.
About Indoximod
Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is a key immuno-oncology target involved in regulating the tumor microenvironment and immune escape. Indoximod is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, cancer vaccines, radiation, and chemotherapy across multiple indications such as melanoma, pancreatic cancer and other malignancies.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2017 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink Genetics’ views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com
Primary Logo
Bounce coming it look like
Baba was good overnight flip
Maybe it goes to high $45’s
Might get in around $47 if it hold AH got a a quick bounce
JILL continues to move up
What happened?
Y’all had better sell here before this turd continues downward
What does that matter when talking how many shares are out there? Lol
Spotify said in updated IPO documents Tuesday that about 162 million of its total 178.1 million shares outstanding will be available on the first day of trading. Daniel Ek, Spotify’s co-founder and CEO, would be eligible to sell his entire stake if he so chooses.
...
WSJ Membership BenefitsCustomer Center
Legal PoliciesDownload WSJ Apps
The Wall Street Journal
Copyright ©2017 Dow Jones & Company, Inc. All Rights Reserved.
THANKS FOR READING
The Wall Street Journal
I read there’s about 160 million that are available though, how many sellers today...who knows. But that a lot of shares available
This will go way down before it finds a bottom
Wish I could short this
How many shares did they price?
.50 coming
There will be some massive selling at the open
Might can get another flip here today
To da moon?!? . Loo
JILL holding up on a bloody day
Not to mention that the entire market is going to be shaky today, so I definitely wouldn’t want to be holding EDGE
RSI on this could easily hit the single digits
Why would this go back up?
Someone better hack something soon and ask to be paid in bitcoin, or this is going to zer000
So we’re going just going to pretend it wasn’t 250 to 19k to here???
Okie dokie
From 19k to under 7k, I would you’ve been watching a crash the entire time
$3-$4 open Monday I’m thinking
Gums?
2-3 times a day huh??
You must be scalping for a penny at a time...
Besides 1.12-1.34...what’d you flip??
Guns?
All caps make you appear panicked for making such a horrible gamble
New low coming......there’s no reason for it bounce right now.
.26 coming
What happens if none of this IFS occur??
.26 in the next 3 months
This could easily hit .26.
It was a one trick pony that failed.
DD is a must, one of its other pipe line drugs is already under investigation.
There’s no reason for this to bounce anytime soon
Nice bids coming in, just seen a 42k share block
EDGE<AYTU
Back to $5
I’d like to see a .75 break